.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Teva
Federal Trade Commission
Daiichi Sankyo
Deloitte
Healthtrust
Farmers Insurance
Accenture
Dow
US Army

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: RE42462

« Back to Dashboard

Which drugs does patent RE42462 protect, and when does it expire?


Patent RE42462 protects LETAIRIS and is included in one NDA. There has been one Paragraph IV challenge on Letairis.

This patent has sixty-two patent family members in thirty countries.

Summary for Patent: RE42462

Title:Carboxylic acid derivatives, their preparation and use
Abstract: Carboxylic acid derivatives ##STR00001## where R-R.sup.6, X, Y and Z have the meanings stated in the description, and the preparation thereof, are described. The novel compounds are suitable for controlling diseases.
Inventor(s): Riechers; Hartmut (Neustadt, DE), Klinge; Dagmar (Heidelberg, DE), Amberg; Wilhelm (Friedrichsdorf, DE), Kling; Andreas (Mannheim, DE), Muller; Stefan (Speyer, DE), Baumann; Ernst (Dudenhofen, DE), Rheinheimer; Joachim (Ludwigshafen, DE), Vogelbacher; Uwe Josef (Ludwigshafen, DE), Wernet; Wolfgang (Hassloch, DE), Unger; Liliane (Ludwigshafen, DE), Raschack; Manfred (Weisenheim, DE)
Assignee: Abbott GmbH & Co. KG (Wiesbaden, DE)
Application Number:12/481,594
Patent Claim Types:
see list of patent claims
Compound;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
GileadLETAIRISambrisentanTABLET;ORAL022081-001Jun 15, 2007RXYesNo► Subscribe► Subscribe► SubscribeY
GileadLETAIRISambrisentanTABLET;ORAL022081-002Jun 15, 2007RXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: RE42462

PCT Information
PCT FiledOctober 07, 1995PCT Application Number:PCT/EP95/03963
PCT Publication Date:April 25, 1996PCT Publication Number: WO96/11914

Non-Orange Book Patents for Patent: RE42462

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,119,097Carboxylic acid derivatives, their preparation and their use► Subscribe
RE42477Carboxylic acid derivatives, their preparation and use► Subscribe
5,772,589 Measurement process for blood gas analysis sensors► Subscribe
7,582,647Carboxylic acid derivatives, their preparation and use► Subscribe
7,601,730Carboxylic acid derivatives, their preparation and use► Subscribe
7,109,205Carboxylic acid derivatives, their preparation and use► Subscribe
6,197,958 Carboxylic acid derivatives, their preparation and use► Subscribe
7,863,445Carboxylic acid derivatives, their preparation and use► Subscribe
6,600,043 Carboxylic acid derivatives, their preparation and use► Subscribe
8,349,843Carboxylic acid derivatives, their preparation and use► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: RE42462

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria204568► Subscribe
Austria277911► Subscribe
Australia3804595► Subscribe
Australia688611► Subscribe
Brazil9509338► Subscribe
Canada2201785► Subscribe
China1142918► Subscribe
China1160396► Subscribe
China1293059► Subscribe
China1513844► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
Accenture
Baxter
US Department of Justice
McKesson
US Army
McKinsey
Dow
QuintilesIMS
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot